Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
40433 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A44913 | 26845516 | Hepatology | Hepatic mitochondrial dysfunction in nonalcoholic steatohepatitis: Read-out or reason? | 2016 | Details |
| A44914 | 26831187 | Wien Klin Wochenschr | Liver fatty acid-binding protein may be a useful marker for non-alcoholic fatty liver disease but obesity is a major concern. | 2016 | Details |
| A44915 | 26826669 | Gastroenterology | Inflammation in Alcoholic and Nonalcoholic Fatty Liver Disease: Friend or Foe? | 2016 | Details |
| A44916 | 26820053 | Gastroenterology | Magnetic Resonance Imaging/Elastography Is Superior to Transient Elastography for Detection of Liver Fibrosis and Fat in Nonalcoholic Fatty Liver Disease. | 2016 | Details |
| A44917 | 26813365 | Zhonghua Yi Xue Za Zhi | [The pathogenesis and management of non-alcoholic fatty liver disease coexisted with type 2 diabetes]. | 2015 | Details |
| A44918 | 26805015 | Metabolism | Nonalcoholic fatty future disease. | 2015 | Details |
| A44919 | 26790569 | Liver Int | The relationship between serum uric acid levels and the major risk factors for the development of nonalcoholic fatty liver disease. | 2016 | Details |
| A44920 | 26790190 | Pharmazie | Nectandrin B, a lignan isolated from nutmeg, inhibits liver X receptor-α-induced hepatic lipogenesis through AMP-activated protein kinase activation. | 2015 | Details |
| A44921 | 26786686 | Gut | Altered intestinal microbiota as a major driving force in alcoholic steatohepatitis. | 2016 | Details |
| A44922 | 26784140 | Gastroenterology | Is Hepatocellular Cancer the Same Disease in Alcoholic and Nonalcoholic Fatty Liver Diseases? | 2016 | Details |
| A44923 | 26783621 | MMW Fortschr Med | [Weight loss can cure fatty liver]. | 2015 | Details |
| A44924 | 26782133 | Hosp Pract (1995) | The Burden of Rehospitalization for Patients With Liver Cirrhosis. | 2016 | Details |
| A44925 | 26780008 | Curr Opin Lipidol | Gene-based therapies in lipidology: current status and future challenges. | 2015 | Details |
| A44926 | 26775630 | Gastroenterology | How Safe Is Moderate Alcohol Consumption in Overweight and Obese Individuals? | 2016 | Details |
| A44927 | 26775617 | Respirology | Does continuous positive airway pressure therapy improve non-alcoholic fatty liver disease? | 2016 | Details |
| A44928 | 26749112 | J Pediatr | Pediatric Nonalcoholic Fatty Liver Disease: A Report from the Expert Committee on Nonalcoholic Fatty Liver Disease (ECON). | 2016 | Details |
| A44929 | 26743253 | Zhonghua Gan Zang Bing Za Zhi | [Role of vitamin D deficiency in nonalcoholic fatty liver disease]. | 2015 | Details |
| A44930 | 26738480 | Annu Rev Pharmacol Toxicol | Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet? | 2016 | Details |
| A44931 | 26730276 | World J Hepatol | Extragastric manifestations of Helicobacter pylori infection: Possible role of bacterium in liver and pancreas diseases. | 2015 | Details |
| A44932 | 26728014 | J Nucl Cardiol | Hepatic FDG uptake in patients with NAFLD: An important prognostic factor for cardio-cerebrovascular events? | 2016 | Details |
| A44933 | 26707308 | Transplant Proc | Hepatic Steatosis as a Predictive Factor of Antiviral Effect of Pegylated Interferon Therapy in Patients With Hepatitis B. | 2015 | Details |
| A44934 | 26704864 | J Pediatr Gastroenterol Nutr | Plasminogen Activator Inhibitor-1 Predicts Quantity of Hepatic Steatosis Independent of Insulin Resistance and Body Weight. | 2016 | Details |
| A44935 | 26701199 | Comput Methods Programs Biomed | Development of a web-based liver cancer prediction model for type II diabetes patients by using an artificial neural network. | 2015 | Details |
| A44936 | 26699087 | Hepatology | Histidine-rich glycoprotein promotes macrophage activation and inflammation in chronic liver disease. | 2016 | Details |
| A44937 | 26698585 | AMA J Ethics | Enrolling Research Participants in Private Practice: Conflicts of Interest, Consistency, Therapeutic Misconception, and Informed Consent. | 2015 | Details |
| A44938 | 26676812 | Semin Liver Dis | Genetics of Alcoholic Liver Disease. | 2015 | Details |
| A44939 | 26673224 | J Hepatol | TM6SF2 may drive postprandial lipoprotein cholesterol toxicity away from the vessel walls to the liver in NAFLD. | 2015 | Details |
| A44940 | 26664664 | Ont Health Technol Assess Ser | Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis. | 2015 | Details |
| A44941 | 26664429 | J Res Med Sci | Resveratrol and liver: A systematic review. | 2015 | Details |
| A44942 | 26661503 | Hepatology | Therapeutic potential of nicotinamide adenine dinucleotide for nonalcoholic fatty liver disease. | 2016 | Details |
| A44943 | 26655287 | Curr Opin Lipidol | Choline metabolites: gene by diet interactions. | 2016 | Details |
| A44944 | 26654031 | Am J Cardiol | Statins for Improving Myocardial Perfusion in Patients With Nonalcoholic Fatty Liver Disease Undergoing Percutaneous Coronary Intervention. | 2015 | Details |
| A44945 | 26644352 | FASEB J | Second-generation antisense oligonucleotides against β-catenin protect mice against diet-induced hepatic steatosis and hepatic and peripheral insulin resistance. | 2015 | Details |
| A44946 | 26643784 | J Hepatol | Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD? | 2015 | Details |
| A44947 | 26641319 | Expert Rev Gastroenterol Hepatol | Pediatric liver diseases: current challenges and future perspectives. | 2015 | Details |
| A44948 | 26638936 | Aliment Pharmacol Ther | Letter: factors determining liver fibrosis - more to come. | 2016 | Details |
| A44949 | 26638929 | Aliment Pharmacol Ther | Editorial: screening for NAFLD - a promising strategy to mitigate future burden of liver disease. | 2016 | Details |
| A44950 | 26638191 | Hepatology | HEDGEHOG Signal in hepatocytes mediates macrophage recruitment: A new mechanism and potential therapeutic target for fatty liver disease. | 2016 | Details |
| A44951 | 26637457 | J Virol | Hepatitis B Virus X Protein Induces Hepatic Steatosis by Enhancing the Expression of Liver Fatty Acid Binding Protein. | 2015 | Details |
| A44952 | 26632699 | Medicine (Baltimore) | Significant Association Between Adiponutrin and Hepatocellular Carcinoma Risk. | 2015 | Details |
| A44953 | 26629867 | Eur J Gastroenterol Hepatol | Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands. | 2016 | Details |
| A44954 | 26628846 | J Clin Exp Hepatol | Intestinal FXR: A New Therapeutic Target for Nonalcoholic Fatty Liver Disease. | 2015 | Details |
| A44955 | 26625237 | Dtsch Med Wochenschr | [Non-alcoholic fatty liver diseases]. | 2015 | Details |
| A44956 | 26616574 | Gastroenterology | High False-Negative Rate for Nonalcoholic Steatohepatitis in Extreme Obesity. | 2015 | Details |
| A44957 | 26616571 | Gastroenterology | Reply. | 2015 | Details |
| A44958 | 26615875 | Biochim Biophys Acta | Deletion of sphingosine kinase 1 ameliorates hepatic steatosis in diet-induced obese mice: Role of PPARγ. | 2015 | Details |
| A44959 | 26608257 | Lancet | A LEAN treatment for non-alcoholic steatohepatitis. | 2015 | Details |
| A44960 | 26602387 | Intern Emerg Med | Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome. | 2015 | Details |
| A44961 | 26602219 | Gastroenterology | Time to Replace Assessment of Liver Histology With MR-Based Imaging Tests to Assess Efficacy of Interventions for Nonalcoholic Fatty Liver Disease. | 2015 | Details |
| A44962 | 26602217 | Gastroenterology | End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease. | 2015 | Details |
| A44963 | 26592903 | Cardiovasc J Afr | From the Editor's Desk. | 2016 | Details |
| A44964 | 26592819 | Eur Rev Med Pharmacol Sci | Reply to the Letter "Effect of anti-oxidant agents in patients with hepatocellular diseases". | 2015 | Details |
| A44965 | 26592818 | Eur Rev Med Pharmacol Sci | Effect of anti-oxidant agents in patients with hepatocellular diseases. | 2015 | Details |
| A44966 | 26587921 | AJR Am J Roentgenol | Longitudinal Changes in Liver Fat Content in Asymptomatic Adults: Hepatic Attenuation on Unenhanced CT as an Imaging Biomarker for Steatosis. | 2015 | Details |
| A44967 | 26585566 | Endocrine | Periostin on the road to nonalcoholic fatty liver disease. | 2015 | Details |
| A44968 | 26583270 | J Clin Gastroenterol | In Response. | 2016 | Details |
| A44969 | 26576484 | J Hepatol | Reply to "The association between sarcopenia and non-alcoholic fatty liver disease: Potential pitfalls in non-invasive prediction models". | 2015 | Details |
| A44970 | 26576482 | J Hepatol | The association between sarcopenia and non-alcoholic fatty liver disease: Potential pitfalls in non-invasive prediction models. | 2015 | Details |
| A44971 | 26573186 | Zhonghua Gan Zang Bing Za Zhi | [Diagnosis and multimodality therapy for non-alcoholic fatty liver disease]. | 2015 | Details |
| A44972 | 26571774 | Nihon Naika Gakkai Zasshi | [Gut Microbiota and Internal Diseases: Update Information. Topics: III. NASH/NAFLD and gut microbiota]. | 2015 | Details |
| A44973 | 26567082 | Hepatology | We are not in Kansas anymore: The unfamiliar landscape of NASH. | 2016 | Details |
| A44974 | 26566595 | Hepatology | Screening for nonalcoholic fatty liver disease in patients with atherosclerotic coronary disease?--In principle yes, in practice not yet. | 2016 | Details |
| A44975 | 26566312 | J Clin Biochem Nutr | Sitagliptin can inhibit the development of hepatic steatosis in high-fructose diet-fed ob/ob mice. | 2015 | Details |
| A44976 | 26566061 | Eur J Gastroenterol Hepatol | Relationship of hepatic fibrosis, cirrhosis, and mortality with cholecystectomy in patients with hepatitis C virus infection. | 2016 | Details |
| A44977 | 26564715 | Am J Physiol Gastrointest Liver Physiol | Glial cell line-derived neurotrophic factor protects against high-fat diet-induced hepatic steatosis by suppressing hepatic PPAR-γ expression. | 2015 | Details |
| A44979 | 26544701 | AIDS | Transient elastography for the detection of hepatic fibrosis in HIV-monoinfected adults with elevated aminotransferases on antiretroviral therapy. | 2015 | Details |
| A44980 | 26537323 | Nihon Shokakibyo Gakkai Zasshi | [Gut microbiota and NASH]. | 2015 | Details |
| A44981 | 26534773 | Dig Liver Dis | The association between primary bacteremia of presumed gastrointestinal origin and nonalcoholic fatty liver disease. | 2015 | Details |
| A44982 | 26530157 | Am J Physiol Endocrinol Metab | Advances in high-density lipoprotein physiology: surprises, overturns, and promises. | 2015 | Details |
| A44983 | 26526847 | Clin Res Hepatol Gastroenterol | Nonalcoholic steatohepatitis cirrhosis and type 1 refractory celiac disease: More than a fortuitous association? | 2015 | Details |
| A44984 | 26521489 | Sheng Li Ke Xue Jin Zhan | [The role of peroxisome proliferator-activated receptors in the pathogenesis of nonalcoholic fatty liver disease]. | 2015 | Details |
| A44985 | 26517408 | Hepatology | Nonalcoholic fatty liver disease activity score and mortality: Imperfect but not insignificant. | 2016 | Details |
| A44986 | 26515490 | Gastroenterology | Low Carbohydrate Rather Than Low Fat Is More Important in Dietary Management of Nonalcoholic Steatohepatitis. | 2015 | Details |
| A44987 | 26515488 | Gastroenterology | Reply: To PMID 25865049. | 2015 | Details |
| A44988 | 26515481 | J Bioenerg Biomembr | Letter to the Editor: The bioenergetics of hepatic mitochondria isolated from avocado oil-treated rats: typical experimental errors in the study of the bioenergetics of isolated mitochondria. | 2015 | Details |
| A44989 | 26515480 | J Bioenerg Biomembr | Response to the Letter to the Editor "the bioenergetics of hepatic mitochondria isolated from avocado oil-treated rats". | 2015 | Details |
| A44990 | 26513521 | Eur J Gastroenterol Hepatol | Neutrophil-to-lymphocyte ratio for predicting fibrosis in nonalcoholic fatty liver disease. | 2015 | Details |
| A44991 | 26510545 | Aliment Pharmacol Ther | Letter: association between moderate alcohol consumption and non-alcoholic fatty liver disease--authors' reply. | 2015 | Details |
| A44992 | 26510544 | Aliment Pharmacol Ther | Letter: association between moderate alcohol consumption and non-alcoholic fatty liver disease. | 2015 | Details |
| A44993 | 26507940 | Surg Obes Relat Dis | Interpretation of results from the effect of surgically induced weight loss on nonalcoholic fatty liver disease patients. | 2015 | Details |
| A44994 | 26504855 | J Immunol Res | Autoimmune Conditions in 235 Hemochromatosis Probands with HFE C282Y Homozygosity and Their First-Degree Relatives. | 2015 | Details |
| A44995 | 26504484 | Evid Based Complement Alternat Med | Deepure Tea Improves High Fat Diet-Induced Insulin Resistance and Nonalcoholic Fatty Liver Disease. | 2015 | Details |
| A44996 | 26500738 | Infect Dis Rep | Vibrio Vulnificus Necrotizing Fasciitis Associated with Acupuncture. | 2015 | Details |
| A44997 | 26486720 | Hepatology | Nonalcoholic fatty liver disease, cardiovascular outcomes, and mortality in patients undergoing a coronary angiogram. | 2016 | Details |
| A44998 | 26485085 | J Child Adolesc Psychopharmacol | From the Editor-in-Chief's Desk. | 2015 | Details |
| A44999 | 26476299 | Hepatology | Iron absorption in nonalcoholic steatohepatitis and dysmetabolic iron overload syndrome. | 2015 | Details |
| A45000 | 26462490 | Dig Dis Sci | Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy. | 2016 | Details |
| A45001 | 26458864 | Saudi J Gastroenterol | The effect of bariatric surgeries on nonalcoholic fatty liver disease: Erratum. | 2016 | Details |
| A45002 | 26456845 | J Hepatol | Statins and non-alcoholic steatohepatitis. | 2015 | Details |
| A45003 | 26456843 | J Hepatol | Reply to "Statin treatment for non-alcoholic steatohepatitis". | 2015 | Details |
| A45004 | 26455261 | J Agric Food Chem | Gomisin J Inhibits Oleic Acid-Induced Hepatic Lipogenesis by Activation of the AMPK-Dependent Pathway and Inhibition of the Hepatokine Fetuin-A in HepG2 Cells. | 2015 | Details |
| A45005 | 26452651 | Hepatology | Time to Abandon NASH? | 2015 | Details |
| A45006 | 26448455 | Clin Transl Gastroenterol | Circulating Soluble CD163 is Associated with Steatohepatitis and Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. | 2015 | Details |
| A45007 | 26448136 | J Clin Gastroenterol | A Double-blinded Randomized Placebo-controlled Clinical Trial of Omega-3 Fatty Acids for the Treatment of Diabetic Patients With Nonalcoholic Steatohepatitis. | 2016 | Details |
| A45008 | 26447962 | J Clin Gastroenterol | Probiotics in Pediatric Liver Disease. | 2016 | Details |
| A45009 | 26447928 | Hepatology | Noninvasive predictors of fibrosis in NASH with and without cirrhosis, just as good as histology (and hepatic venous pressure gradient?). | 2015 | Details |
| A45010 | 26447628 | Zhonghua Gan Zang Bing Za Zhi | [Epidemiological investigation of fatty liver disease in Northwest China]. | 2015 | Details |
| A45011 | 26447618 | Zhonghua Gan Zang Bing Za Zhi | [Cholestasis morbidity rate in first-hospitalized patients with chronic liver disease in Shanghai]. | 2015 | Details |
| A45012 | 26446314 | Hepatology | NASH, from diagnosis to treatment: Where do we stand? | 2015 | Details |
| A45013 | 26443794 | J Lipid Res | Recent insights into the biological functions of liver fatty acid binding protein 1. | 2015 | Details |